Skip to main content

Table 4 Meta-12 genes with outlier expression in > 80% (12/15) high-grade NEPC patients

From: Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma

Gene NEPC outliers % NEPC [15] % AdCa [114] % Ad+NED [5] NEPC centroid AdCa centroid
Up genes
 AP3B2 15 100 6 80 8.5 6.5
 TUBB2B 14.4 96 4 0 11.8 7.3
 CRMP1 14 93 4 60 9.9 6.7
 PCSK1 14 93 3 20 10.8 6.2
 SEZ6 14 93 4 60 8.5 6.5
 CDC25B 13.8 92 7 0 11.5 9.5
 KCNC1 13.8 92 2 40 7.8 5.7
 TMEM145 13.7 91 6 40 11.7 9.1
 CCDC88A 13.4 89 4 40 9.0 7.6
 ASCL1 13.3 89 5 0 10.9 6.8
 ENO2 13.2 88 5 0 11.6 9.4
 MIAT 13.1 87 6 0 10.1 7.1
 SRRM4 13.1 87 5 40 8.8 6.4
 NPTX1 13 87 4 0 10.7 7.2
 PHF19 13 87 6 0 10.8 9.2
 RNF183 13 87 6 0 9.4 7.2
 TOX 13 87 4 40 8.6 6.2
 INSM1 12.9 86 4 0 10.1 6.9
 IGFBPL1 12.8 85 6 0 9.5 7.1
 ELAVL3 12.6 84 2 60 7.7 6.0
 RUNDC3A 12.6 84 5 20 9.1 7.0
 NKX2-1 12.5 83 5 0 10.0 7.8
 UNC13A 12.5 83 6 100 7.8 6.0
 FANCL 12.4 83 1 0 12.3 11.6
 SH3GL2 12.4 83 4 20 10.0 7.0
 FAM161A 12.1 81 6 0 9.6 8.9
 APLP1 12 80 4 40 9.3 7.2
 DLL3 12 80 4 40 9.2 6.7
 DNMT1 12 80 4 20 10.5 8.7
 ELAVL4 12 80 3 50 7.7 5.7
 FGF9 12 80 6 0 9.5 7.3
 INA 12 80 8 20 11.0 7.6
 NPPA 12 80 4 0 8.6 5.9
 PCSK2 12 80 1 0 8.1 5.5
 SNAP25 12 80 8 100 9.5 6.2
 SOX2 12 80 5 0 11.0 7.3
 STMN1 12 80 3 0 10.6 9.9
Down genes
 AR 14.3 95 5 0 7.0 13.3
 AIM1 14.3 95 5 20 7.7 10.2
 ADRB2 14 93 3 20 7.8 11.5
 SPDEF 14 93 4 0 8.9 12.0
 STEAP1 14 93 5 0 7.0 12.7
 STEAP2 14 93 6 0 7.6 13.3
 C1orf116 13.9 93 4 0 7.8 11.4
 ERGIC1 13.9 93 5 0 8.2 10.5
 LATS2 13.8 92 4 0 7.3 10.5
 NKX3-1 13.6 91 6 0 8.9 14.9
 PMEPA1 13.6 91 4 0 10.2 14.5
 HOMER2 13.4 89 3 0 7.8 10.9
 ZBTB16 13.4 89 5 0 8.3 12.4
 ZG16B 13.4 89 4 0 8.2 13.0
 EPHX2 13.1 87 2 0 9.1 12.5
 SLC45A3 13 87 5 0 9.1 14.6
 GLUD1 12.7 85 4 0 10.0 12.7
 SLC44A4 12.7 85 5 20 7.5 10.5
 CCND1 12.6 84 8 40 6.9 10.1
 KLK3 12.6 84 4 0 9.3 12.8
 PPAP2A 12.6 84 7 0 10.7 14.8
 GRTP1 12.5 83 4 0 6.0 7.9
 YAP1 12.5 83 4 60 6.4 9.1
 SYNGR2 12.4 83 4 0 10.8 13.0
 ALDH6A1 12.3 82 2 0 8.7 11.7
 NAP1L2 12.3 82 5 0 6.3 9.8
 HPN 12.2 81 5 20 8.0 11.3
 RGS10 12.1 81 4 0 10.1 14.1
 RILPL2 12.1 81 4 0 9.1 11.4
 ACPP 12 80 3 20 7.3 11.5
 HOXB13 12 80 6 0 10.4 14.2
 ICAM3 12 80 6 0 8.7 11.0
  1. Legend: List of meta-12 genes with % outlier status [# patients] among meta-analysis patients (NEPC, adenocarcinoma, or adenocarcinoma with NE differentiation). Centroids were formed by averaging each gene over NEPC or adenocarcinoma patients